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Aspirin-exacerbated respiratory disease (AERD) refers to chronic rhinosinusitis, nasal polyposis, bronchoconstriction, and/or
eosinophilic inﬂammation in asthmatics following the exposure to nonsteroidal anti-inﬂammatory drugs (NSAIDs). A key
pathogenic mechanism associated with AERD is the imbalance of eicosanoid metabolism focusing on prostanoid and leukotriene
pathways in airway mucosa as well as blood cells. Genetic and functional metabolic studies on vital and non-vital cells pointed
to the variability and the crucial role of lipid mediators in disease susceptibility and their response to medication. Eicosanoids,
exempliﬁed by prostaglandin E2 (PGE2) and peptidoleukotrienes (pLT), are potential metabolic biomarkers contributing to the
AERD phenotype. Also other mediators are implicated in the progress of AERD. Considering the various pathogenic mechanisms
of AERD, a multitude of metabolic and genetic markers is suggested to be implicated and were introduced as potential biomarkers
for in vitro diagnosis during the past decades. Deduced from an eicosanoid-related pathogenic mechanism, functional tests
balancing PGE2 and pLT as well as other eicosanoids from preferentially vital leukocytes demonstrated their applicability for
in vitro diagnosis of AERD.
1.Introduction
Diagnostic tests assist the physician in assuring an appro-
priate treatment of the symptoms and as also the disease
from which a patient is suﬀering. In vitro diagnostic tests
are widely used in the practice of modern medicine. Nons-
teroidal anti-inﬂammatory drugs (NSAIDs) are amongst the
most frequently used drugs for the treatment of a variety
of symptoms and diseases. Therefore, it is unsurprising that
adverse reactions to NSAIDs arise in some patients.
The diagnosis of NSAID-triggered, or exacerbated symp-
toms and diseases, is usually based on medical history or
provocative challenge testing [1–8]. In some cases the latter
is precluded on ethical grounds (e.g., pregnancy, children
of young age), anatomical alterations (e.g., massive nasal
polyposis),missingcomplianceofthepatient(e.g.,asthmatic
experiences and therefore fear of life threatening symptoms),
unavailabilityofspeciﬁctechnicaland/ormedicalequipment
(e.g., measurement of respiratory function, appropriate
emergency unit), or inadequately trained staﬀ [7, 8].
Several approaches attempted to diagnose and conﬁrm
NSAID-triggered symptoms and related diseases by in vitro
diagnostic tools during the last 110 years. Some of them
were discarded, others are under investigation. In vitro tests,
and the results derived when they are used, frequently play
a vital role in the overall diagnostic process. To ensure that
each reader has the same basic knowledge, we will describe
some rudimentary background information on terminology,
suggestedpathomechanism,testtheoryandtestperformance
before discussing the in vitro test for diagnosis of NSAID-
triggered symptoms and underlying diseases in more detail.
To some extent there is a known discrepancy of medical
history and clinical symptoms upon exposure to NSAIDs,
that is, that the provocation test shows negative outcome,
whereas patients’ history documented positive reaction. This
may require an additional (in vitro) diagnosis to support
the physician’s decision for an appropriate treatment of the
patient. Unfortunately, any diagnostic procedure, clinically
and in vitro, is hampered by one or more inherent as well2 Journal of Allergy
Table 1: Terms used for reactions of NSAID-triggered hypersensitivity. NSAID: nonsteroidal anti-inﬂammatory drugs; COX: cyclooxyge-
nase.
Terms used Predominant manifestation/location
of symptoms Supposed underlying pathomechanism
Syndrome de Widal Airways Pathomechanism unknown, hyperreactivity/-sensitivity to aspirin
and aspirin-like drugs
Samter’s triad Airways Pathomechanism suspected to altered sensitivity of chemoreceptor,
hyperreactivity of airway mucosa to aspirin and aspirin-like drugs
Aspirin idiosyncrasy Anywhere, ubiquitous
“Peculiarity” of hypersensitive reaction to aspirin and aspirin-like
drugs which is not elicit by immunoglobulin-mediated/immunologic
reactions, but by dysfunction or loss of function of enzymes
Aspirin allergy Anywhere, Ubiquitous Involvement of immunoglobulin-mediated/immunological reactions
directed to aspirin and aspirin-like drugs
Pseudoallergic reaction to
aspirin Anywhere, ubiquitous
Reaction to aspirin and aspirin-like drugs, causing symptoms as seen
by allergic, reactions (i.e., immunoglobulin-mediated/immunologic),
but without involvement of immunological reactions
Aspirin intolerance Anywhere, ubiquitous Pathomechanism unknown/not deﬁned, but aspirin and aspirin-like
drugs are not tolerated by an individual
Aspirin sensitivity Anywhere, ubiquitous Pathomechanism unknown, but hyperreactivity/-sensitivity to
aspirin and aspirin-like drugs, symptomatic description
Aspirin-sensitive asthma Lower airways Hyper-reactivity to aspirin and aspirin-like drugs causing airway
obstruction
Aspirin-induced asthma Lower airways Pathomechanism unknown, but initiated/induced by aspirin and
aspirin-like drugs
Aspirin-exacerbated
respiratory disease (AERD) Airways, systemic Exacerbated by NSAIDs blocking COX-1 pathway
NSAID-induced rhinitis
and asthma (NIRA) Airways Exacerbated by NSAIDs blocking COX-1 pathway
NSAID-induced
urticaria/angioedema
(NIUA)
Skin, systemic Exacerbated by NSAIDs blocking COX-1 pathway
Single drug-induced
urticaria/angioedema
(SDUA)
Skin Exacerbated by a single NSAID blocking COX-1 pathway
Multi-drug-induced
urticaria/angioedema
(MDUA)
Skin Exacerbated by multiple NSAIDs blocking COX-1 pathway
Single drug-induced
anaphylaxis (SDA) Systemic Sensitisation to a single NSAID blocking COX pathway, suggested
immunoglobulin-mediated/immunologic pathomechanism
NSAID-blended reaction
(NBR) Airways, skin Pathomechanism unknown; not AERD, not NIRA, presumably not
immunoglobulin-mediated/immunologic
as exogenous factors. While some of them are known, most
remain unknown, leading to some uncertainty of the test
outcome.
The nomenclature for NSAID-triggered hypersensitivity
reaction in medical literature might be confusing because of
the diverse terms employed over last decades and the multi-
ple clinical manifestations in humans. A list of terms used is
giveninTable 1,makingnoclaimtobecomplete.Supporting
the communication we consider the proposed terminology
of “Report of the Nomenclature Review Committee of the
World Allergy Organisation”, dating from 2003 [7]. This
nomenclature is independent of the target organ or patient
age group, but is based on the mechanisms that initiate and
mediate reactions on our current knowledge, assuming that
as knowledge about basic causes and mechanisms improves,
the nomenclature will need further review. In this context
“hypersensitivity” describes objectively reproducible symp-
toms or signs initiated by exposure to a deﬁned stimulus at a
dose tolerated by normal persons. The terminology “aspirin-
exacerbated respiratory disease” (AERD) characterises phys-
ical reactions, underlying respiratory diseases, and inhibitors
of cyclooxygenase (COX) and refers to the clinical syndrome
of chronic rhinosinusitis (CRS), nasal polyposis, bron-
choconstriction in asthmatics, and/or eosinophil inﬂamma-
tion in the upper and lower airways following the ingestion
of NSAIDs blocking the COX-1 enzyme [9]. An assignment
of AERD in the context of adverse drug reactions (ADR) and
drug hypersensitivity is given in Figure 1.
NSAIDs are colloquially named “aspirin” or “aspirin-like
drugs”. Aspirin, the trade name of acetylsalicylic acid (ASA),Journal of Allergy 3
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Figure 1: Allocation of terms used for adverse reactions to drugs. The diagram ﬁles the term AERD in the context of ADR, drug
hypersensitivity, and drug allergy. The terms were gathered from “Report of the Nomenclature Review Committee of the World Allergy
Organization” [7], and the proposed classiﬁcation of allergic and pseudoallergic reactions to drugs that inhibit cyclooxygenase enzymes
[9]; AERD: aspirin-exacerbated respiratory diseases, NSAID: nonsteroidal anti-inﬂammatory drugs, NIUA: NSAID-induced urticaria/angi-
oedema, NBR: NSAID-blended reaction, SDA: single drug-induced anaphylaxis. Deﬁnition of ADR according to the World Health
Organization[10]:anynoxious,unintended,andundesiredeﬀectofadrug,whichoccursatdosesusedinhumansforprophylaxis,diagnosis,
or therapy. This deﬁnition excludes therapeutic failures, intentional and accidental poisoning (i.e., overdose), and drug abuse.
patented in 1899 by Bayer AG in Germany and in 1900 in the
USA, was thereafter successfully marketed all over the world
and still remains one of the world’s safest, least expensive,
and most frequently used drug [12]. In vivo absorption of
salicylateandacetylsalicylicacidvariesgreatlyfromoneindi-
vidual to another but is reasonably constant within the same
individual. Bound and unbound salicylate shows no diﬀer-
ences in aspirin-tolerant and aspirin-intolerant patients, and
the rate of deacetylation in serum is the same for aspirin-
intolerantpatientsandnormalcontrols[3,13].Thepharma-
cologicalhallmarkofacetylsalicylicacidandotherNSAIDsis
the blocking of COX-enzymes causing reduction and/or loss
of prostaglandin (PG) production as demonstrated in 1971
by Ferreira and colleagues [14], Smith and Willis [15], and
Vane [16]. Meanwhile there are several other NSAIDs known
to inhibit the three known COX-isoenzymes, depending on
their selectivity (an overview is given in Table 2,f o rr e v i e w
see [17]).
The characterisation of NSAID-triggered airway diseases,
AERD, was ﬁrst published by Widal et al. in 1922 [2]
describing the symptoms, and was annotated by the eponym
“Syndrome de Widal.”A si tw a sw r i t t e ni nF r e n c hi tw a sn o t
until Samter and Beers popularised this syndrome 35 years
later and the syndrome was annotated “Samter’s triad”[ 3].
Severe cutaneous and systemic adverse reactions upon inges-
tion of “aspirin” was ﬁrst documented in 1902 by Hirschberg
[1],shortlyafterthemarketlaunchofaspirin.Nearly90years
ago it was proposed that aspirin activates rather than inhibits
peripheral chemoreceptors causing bronchoreactivity [18],
increases blood ﬂow, vascular permeability in skin and
permeability of various membranes, bronchoconstriction,
secretion of mucous glands, and alters in aspirin-intolerant
patients [19]. Although NSAIDs, and aspirin in particular,
are beneﬁcial for their indicated use for most patients, these
drugs account for 21–25% of all adverse drug reactions [20].
NSAIDs are well-known elicitors of upper and lower airway
diseases and symptoms of other organs of adults as well as of
children [5, 6, 8, 21].
Symptom-based diagnosis of AERD is usually performed
bymedicalhistory,whichisconﬁrmedbyinvivoprovocation
tests. For this purpose, oral, nasal, bronchial, or intravenous
challengeswithNSAIDsblockingtheCOX-1enzymeareper-
formed followed by measuring of nasal or pulmonary func-
tion [4–9, 12, 22]. The most common causes of adverse drug
reactions are acetylsalicylic acid (∼80%), ibuprofen (41%),
and pyrazolones (∼9%), but also nonselective COX-2 inhi-
bitors are implicated. Medication, usage, and availability are
mostlikelytoberesponsibleforregionaldiﬀerencesconcern-
ing published prevalence of adverse reactions to single
NSAIDs. Therefore, the prevalence of aspirin hypersensi-
tivity in the general population ranges from 0.6 to 2.5%
a n di su pt o∼30% in asthmatics also suﬀering from chro-
nic nasal polyposis. The risk of severe adverse eﬀects caused
bychallengetests,ethicalreasons,and/orothercontraindica-
tions (see above) make an in vitro diagnostic test for AERD
desirable [7, 8].4 Journal of Allergy
Table 2: NSAIDS: classiﬁcation, mechanism of action, representative structures. NSAIDs can be classiﬁed based on their chemical structure
or mechanism of action; older NSAIDs were classiﬁed by chemical structure or origin, newer ones more often by their mechanism of action;
COX: cyclooxygenase, 5-LO: 5-lipoxygenase.
Chemical class Example Inhibitory action Representative example
Salicylates
Acetylsalicylic acid
(Aspirin), diﬂunisal,
mesalamine, salsalate
Nonselective; COX-1,
COX-2,
Acetylsalicylic acid
OH
O
O
O
CH3
Propionic acid derivatives
Fenoprofen, ﬂurbiprofen,
ibuprofen, ketoprofen,
naproxen, oxaprozin
Nonselective, COX-1,
COX-2
Ibuprofen
OH
O
CH3
CH3
H3C
Acetic acid derivatives
Diclofenac, etodolac,
indomethacin, ketorolac,
nabumetone sulindac
Nonselective, COX-1,
COX-2
Diclofenac
OH
O
NH
Cl
Cl
Enolic acid (oxicam)
derivatives
Droxicam, isoxicam
meloxicam, piroxicam,
tenoxicam
Nonselective, preferential
COX-2
Meloxicam
N
N S
S
N
H
OH
O O
O
Sulphonanilides Nimesulide Nonselective, preferential
COX-2
Nimesuleid
S
O
O
O
NH
NO2
Selective COX-2 inhibitors
(coxibs)
Celecoxib, parecoxib,
etoricoxib COX-2
Celecoxib
N
N
S
CF3 H2N
OO
H3C
p-amino phenol derivatives Paracetamol, phenacetin COX
N
H
OH
O
Paracetamol
Fenamic acid derivatives
(fenamates)
Acid, ﬂufenamic acid,
meclofenamic, mefenamic
acid
COX
N
H
OH O
CH3
Cl
Flufenamic acid
Others Licofelone COX, 5-LO
N
OH
O
Cl
LicofeloneJournal of Allergy 5
In vitro diagnosis of AERD is discussed in literature with
some controversy, most likely based on insuﬃcient and in
part contradicting data of earlier and recent publications, as
well as by former papers mentioning the unavailability of or
inability to establish in vitro tests [4, 9]. Most clinicians have
some acquaintance of their use. However, the underlying
concepts pertaining to diagnostic tests in general, and to
their use for diagnosis of a diseases in particular, are often
less familiar, and perhaps less well understood. The current
conceptspointtothepathwaysoflipids(exempliﬁedbyeico-
sanoids)andothermoleculesrelatedtothem(e.g.,cytokines,
growth factors, cell surface markers, second messengers of
cell signalling, enzymes and receptors). These will be sum-
marised in brief and completed by some basic theoretical
aspects.
Eicosanoids (notation introduced in 1980 by Corey et al.
[23], a shorthand nomenclature of eicosanoids was given in
1987 by Smith and Willis [24]) are oxygenated metabolites
of the (5Z,8 Z,1 1 Z,1 4 Z)-5,8,11,14-eicosatetraenoic acid,
widely known as arachidonic acid (AA). Arachidonic acid is
the main source of the eicosanoid cascade in humans involv-
ing more than 50 enzymes generating a multiplicity of eico-
sanoids [25, 26]. Concerning NSAID-triggered hypersensi-
tivityandAERD,weselectedandfocusedontheCOX-and5-
lipoxygenase (5LO-) pathway. Both pathways are intimately
linked to AERD and their implication is well documented
(see subsequent literature). Beside these pathways and their
metabolites, others such as those of cytokines, growth fac-
tors, or second messengers of signal transduction are also
known to be implicated in AERD and related diseases. How-
ever, it is beyond the scope of this paper to cover all of them
in known detail.
Via the COX-pathway prostanoids (i.e., prostaglandins
(PG), thromboxane (TX)) are generated. The COX-pathway
is blocked by NASIDs [14–16, 27] by acetylating the COX
enzyme [28] and by causing inhibition of the conversion
of arachidonic acid to PG [16]. COX-1 is constitutively
e x p r e s s e di nm o s tt i s s u e sa n dc e l l sa n di si n v o l v e di nc e l l u l a r
housekeeping functions. COX-2 is induced by inﬂammatory
stimuli such as cytokines, growth factors, immunoglobulins,
or bacterial toxins. Putative COX-3 mRNA is present in
several tissues, including that from humans, but functional
protein was still not found in humans. COX-3 is switched
on later in inﬂammation and is suggested for biosynthesis
of endogenous anti-inﬂammatory mediators. Its clinical
relevance to COX-3 remains unproven. All COX isoenzymes
are modiﬁed by NSAIDs with diﬀerent eﬃcacy (for review
see [17, 27, 29]). The resulting metabolite PGH2 is further
metabolised by PGE-synthase forming PGE2. The complex-
ity of COX expression was demonstrated for human airways.
There were no diﬀerences in the total number of cells stained
for COX-1 and COX-2 irrespective of whether tolerant
or intolerant to NSAIDs. The number and percentage of
mast cells, however, that express COX-2 was signiﬁcantly
increased in patients intolerant to NSAIDs. Furthermore, the
expression of COX-2 in epithelial and submucosal cellular
wasincreasedinasthmatics[30].Additionally,theexpression
of COX-2 was downregulated in polypous tissue as well as in
bronchial muscular cells from patients with AERD [31, 32].
PGE2 acts on at least four diﬀerent seven-transmembrane-
domain G-protein-coupled receptor subtypes, nominated
EP1 to EP4. Binding on the EP2 or EP4 causes bronchodilata-
tive eﬀects, whereas binding to EP1/EP3 causes opposite ef-
fects [24].
The lipoxygenase pathway comprises several enzymes,
generating several leukotrienes (LT). Focusing on the 5LO-
pathway, LTA4 is generated from AA, which is further
metabolised by the LTC4-synthase forming LTC4, containing
three amino acid groups, which is actively exported in the
extracellular space. An overexpression of the promotor of
the LTC4-synthase gene was observed in some patients with
AERD [33]. The amino acids are degraded by subsequent
enzymatic processes forming LTD4 and LTE4. These metabo-
lites have been named in 1960 by Brocklehurst as slow-react-
ing substances of anaphylaxis (SRS-A) [34] and were identi-
ﬁed in 1982 by Hammarstrom and Samuelsson introducing
the term leukotrienes for their occurrence in leukocytes
and the characteristic chemical structure of conserved three
conjugated double bonds (see Figure 2). These LT are cha-
racterised by a short half-life compared to other lipid
mediators and are collectively named peptidoleukotrienes
(pLT) based on their integral part of amino acids [35, 36].
The discovery of the 5-LO pathway caused an enormous
interest in this area, largely displacing the “classic” prost-
aglandins.pLTarepotentvaso-andbronchoconstrictorsand
have several other biological activities, including an ability to
increase vascular permeability or to produce negative iono-
tropiceﬀectsincardiaccontractions[37,38].ThepLTunfold
their potential by currently three known seven-transmem-
brane-domain G-protein-coupled receptor types, named
cysLT1 and cysLT2. A third dual orphan receptor GPR17
binds uracil nucleotides and pLT [39, 40]. Increased expres-
sion of cysLT1 and cysLT2 receptors is correlated to AERD
[41–43].
The chemotactic metabolite LTB4, also generated from
LTA4 but formed by a separate enzymatic pathway, is 100-
fold less potent concerning bronchoconstriction and acts on
a separate LTB4 receptor [38, 44]. Other lipid mediators are
lipoxins (LX). LXA4 is known to inhibit LTC4 response and
is decreased in patients with AERD [45, 46]. Further patho-
genetic aspects in AERD are extensively reviewed by Palikhe
et al. in this journal [47].
Attempting to condense the ﬁndings outlined above, a
complex eicosanoid-protein interaction network has been
discovered over the past decades, comprising lipid-deriv-
ed mediators, second messengers, cytokines, receptors, enzy-
mes, and activation of genes. Eicosanoids have a crucial role
as mediators in inﬂammatory diseases like AERD. The en-
zymes and receptors of the eicosanoid cascade are found to
bequiteubiquitousbutalsofeaturediﬀerencesregardingdis-
tribution and expression in tissue and cells in normal cir-
cumstances as well as in patients with AERD. The COX-
pathway can be attributed to the control of proliferative
states, the 5LO-pathway to wound healing and tissue repair.
Both pathways are embedded in other metabolic pathways,
for example, the network of cytokines and neuropeptides,
which in turn are also interconnected [48]. Gene expression
and variability diﬀers between AERD and NSAID-tolerant6 Journal of Allergy
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Figure 2: COX and 5-LO pathway in the metabolism of PGE2 and pLT for in vitro diagnosis of NSAID-triggered hypersensitivity.
Simpliﬁed pictogram of eicosanoid pathways in the metabolism PGE2 and leukotrienes implicated for in vitro diagnosis of NSAID-triggered
hypersensitivity. AA is enzymatically cleaved by calcium-dependent PLA2 from phospholipids (predominantly) or from DAG (minor
amounts). AA is metabolised by the COX-pathway or 5-LO pathway (but also by several other pathways not ﬁgured out here). COXs
generate PGH2, which is further processed by PGE-synthase forming PGE2 (other PGH2 metabolising pathways not mentioned here). PGE2
binds to EP subtypes of which EP2 and EP4 generate cAMP for signalling cascade. cAMP in turn causes negative feedback on the 5-LO
pathway. AA is also metabolised by the 5-LO pathway (in part assisted by FLAP) generating LTA4.L T A 4 is further processed by calcium-
dependent LTA4-synthase forming amino acids bearing LTC4, which is exported and extracellularly metabolised by enzymes forming LTD4
and LTE4, collectively named pLTs All three LTs bind to cysLTs or GPR17 with diﬀerential selectivity. 5-LO: 5-lipoxygenase, AA: arachidonic
acid, ASA: acetylsalicylic acid, cAMP: cyclic-adenosine monophosphate; cysLT: receptor of pLT, DAG: diacylglycerole, COX: cyclooxygenase,
EP: PGE-receptor,GPR17: orphan receptor, binding pLT and nucleotides, HPETE: hydroxyperoxy-eicosatetraenoic acid, HETE: hydroxy-
eicosatetraenoic acid, NSAID: nonsteroidal anti-inﬂammatory drugs, PLA2: phospholipase A2, PG: prostaglandin, pLT: peptidoleukotrienes.Journal of Allergy 7
individuals with peculiarities with respect to ethnic back-
ground.
Some of these elements may directly interact with intra-
cellular eﬀectorstotriggermultiplesignallingcascades,while
others act extracellularly. These components control and
modulate cell migration, growth, proliferation, and activity
of tissues and organs, which will result in diﬀerentiated reac-
tions, unveiling symptoms like CRS, nasal polyposis, or asth-
ma. A schematic overview is pictured in Figure 2.
2.Concept of PathogenicMechanisms
We will mention some of the known pathogenic mecha-
nisms, elaborated in respect to AERD and to their supposed
relevance to AERD, but limited to in vitro diagnosis of AERD
and NSAID-triggered hypersensitivity.
Since the ﬁrst description of adverse reactions to aspirin
in airways [2], it is common knowledge that AERD is trig-
gered by NSAIDs [3–9, 11–13, 21, 22, 30, 43, 46, 47, 49–52].
NSAIDSareknowntomodifythemetabolismofunsaturated
lipids, pinpointing eicosanoids [16]. Eicosanoids comprises
a complex network of lipids essentially involved in the
pathomechanisms of NSAID-triggered hypersensitivity or
AERD.
NSAID hypersensitivity is characterised by an imbalance
of eicosanoid synthesis (i.e., PGE2 and pLT) prior to as well
as after exposure to aspirin. This was initially documented in
1999 as a result of analysing cultured peripheral blood cells
[49] as well as nasal mucosa of the same patients [50]. The
concept of the imbalance of eicosanoid synthesis [49]w a s
taken up and approved recently by a theoretical study [51]
and supported by former studies [52]. The genetic as well as
functional modiﬁcations may be reasonable [33, 41–43, 46–
51] but details are not fully understood, as expression of
COX-2 is enhanced in macrophages [48] but no diﬀerences
of COX-1 or COX-2 expression in patients with AERD and
NSAID-tolerant individuals is found [30].
The reduced levels of PGE2 in AERD might be one initial
factor for a diminished endogenous inhibition of the house-
keeping function of PGE2, when activating the EP2 or EP4
receptor. These receptor types initiate the production of
cyclic adenosine monophosphate (cAMP), a second mes-
senger, after binding of PGE2 [48]. The synthesis of pLT is
reduced by a cAMP-dependent intracellular signal transduc-
tion mechanism [11, 48, 52].
Thereducedbasalsynthesisofhousekeepingandinduced
PGE2 [11,49–52],aswellasthepostulated[49]andvalidated
overexpression of LTC4-synthase [33]a n dc y s L Tr e c e p t o r s
[41–43] give rational arguments to explain at leastin part the
shift toward an elevated basal synthesis of pLT. This PGE2-
pLT shift will be further elevated upon exposure to NSAIDs,
but also by other agents initiating the eicosanoid cascade
(e.g., cytokines like interleukine-1, or bacterial antigens).
Thus, the reduced housekeeping/induced PGE2 most likely
accounts for reduced production of cAMP, which is induced
upon coupling of PGE2 on EP2 or EP4 receptors, but can be
induced by other signal transduction pathways [48].
Thus, the diminished availability of the housekeeping
(basal) and induced PGE2 will cause a reduced generation
of suppressive acting endogenous cAMP upon exposure to
COX-inhibiting agents.
In this context, PGE2, pLT, NSAIDs, cAMP, and other
factors (e.g., bacterial toxins, availability of arachidonic
acid, cytokines, and others) will most likely contribute in a
highly complex manner to the multifactorial exacerbation of
NSAID-triggered symptoms and diseases.
3. Theoretical Consideration of
In Vitro Diagnosis
Since the latter half of the 1980s enzyme immunoassay (EIA)
tests are widely used to screen and diagnose a multitude of
diseases. Results are mostly classiﬁed by a binary outcome as
“positive” (“reactive”) or negative (“nonreactive”), based on
the protocols provided by the test manufacture and evalua-
tion in the laboratory. The classiﬁcation is the result of an
ordered sequence of several steps, which had been initiated
via the testing procedure.
Measurement repeatability and reproducibility are inves-
tigated during the approval process. For convenience, we will
assume that the laboratory performing the test will maintain
the complex process of the measurement system, and that
thedistributionoftheresultsof“disease-free”and“diseased”
individuals are normally distributed (see Figure 4).
In an “ideal” world these two normal distributions will
not overlap. Regrettably the world of diagnostic testing is
rarely unequivocally ordered. Many (currently and probably
in perpetuity) unknown factors alter these distributions
causing overlap to some extent. Regardless of where the test
outcome threshold is situated on the measurement scale,
some disease-free individuals and diseased (i.e., AERD) will
be incorrectly classiﬁed as “negative” (known as “false-nega-
tive,” dark shaded area left-hand side of Figure 4) or “posi-
tive” (known as “false-positive,” grey area right-hand side of
Figure 4), respectively. This represents one type of diagnostic
test error.
Because any diagnostic test procedure has a single out-
comethreshold,movingthethresholdtotherightwillreduce
the false-positive results of disease-free individuals, but auto-
matically will increase the false-negative error rate of the di-
seased individuals. Similarly, adjusting the threshold to the
leftwillreducethefalse-negativeerrorrate,butautomatically
increases the false-positive error rate (i.e., classifying disease-
free individuals as patients with AERD).
Only changing the distribution of test results in one or
both groups would simultaneously reduce the rates of both
types of diagnostic test errors (i.e., false-positive and false-
negative results). Unfortunately, in realty this will not be
practicable, due to the complex pathomechanisms underly-
ing AERD, and the composition of the groups investigated
like age, sex, medication, mentioned symptoms, interin-
dividual variability of symptoms and syndromes, and our
limited knowledge and understanding of the “plus-minus”
clearly deﬁned disease [53].
The terms sensitivity (SE), speciﬁcity (SE), and posttest
probabilities in this concern refer to probability of an (in
vitro) diagnostic test outcome, not to the equality of re-
agent or chemicals. Tests with a high sensitivity will correctly8 Journal of Allergy
identify virtually all patients with NSAID-triggered hyper-
sensitivity with a high probability; tests with high speciﬁcity
identify all disease-free individuals correctly with a high pro-
bability. This becomes obvious when referring to Figure 4:
sensitivity and speciﬁcity correspond to the area under the
probability curve (i.e., the distribution) of patients with
NSAID-triggered hypersensitivity (sensitivity of the test, on
the right) and disease-free individuals (speciﬁcity of the test,
on the left). Unfortunately, inadequacies in the pathological
and clinical symptoms or comorbid components and symp-
tom stage, including age and sex distribution of disease-free
individuals as well as patients with disease were described
∼30 years ago [54] and continued to hamper any diagnostic
test [53].
What physicians are really interested in knowing is the
extent to which a positive or negative test result accurately
predicts the true status of the patient, that is, disease-free or
patient with, for example, AERD. This is commonly referred
toastheposttestprobabilityofadisease(e.g.,AERD),orpre-
dictive value of a positive test result (PPV). In case of a neg-
ative test result the posttest probability of being disease-free,
that is, the predictive value of a negative test result (NPV)
is of interest. These values depend on not only the sen-
sitivity and speciﬁcity, but also on the pretest probability (or
prevalence) of the disease (e.g., AERD). The mathematical
algorithm connecting the three probabilities sensitivity,
speciﬁcity, and prevalence is known as Bayes’ theorem (orig-
inally published 1763 by R. Price [55] after the death of the
EnglishclergymanThomasBayes).Itmightbeeasiertograsp
the sense of this relationship more directly than looking
on the mathematical algorithm: the prevalence of AERD is
arguable in respect to the supposed prevalence of 1.2 to 2.8%
of a population [5, 8, 20]. However, as outlined before, there
is some uncertainty concerning the prevalence (i.e., the pre-
test probability) of AERD due to the impossibility of di-
agnosing this syndrome by an absolute unfailing method.
This marks a further limitation for “precisely” deﬁning the
outcome of an in vitro test by mathematical characteristics.
The probability term likelihood ratio, introduced in 1968
by Lustedt and popularised in the 1980s by Sacket et al. is
a ratio of the two probabilities sensitivity and 1-speciﬁcity,
describing the relative probability of a positive diagnostic
test result in diseased individuals compared to disease-free
individuals which can be calculated [56, 57]. For ruling-in
ad i s e a s ethe likelihood ratio should be at least 1, preferably
muchhigher(graphicallythisrepresentstheareaontheright
site of the test threshold of Figure 4). In case of ruling out a
disease, the likelihood ratio of a negative test result is chosen.
These values should ideally be much smaller than one.
As easily deduced from the above-mentioned aspects, the
deﬁnition of an optimal threshold is not only a question of
statistics but rather depends on how the test result will be
used. For screening purpose the threshold will be relative-
ly low, resulting in higher false-positive outcomes. This re-
quires additional diagnostic testing to ensure a therapeutic
regime. In case of AERD a low threshold line will capture
all patients, even those without obvious symptoms. The low
threshold also covers the risk that a patient with a poten-
tial NSAID-triggered hypersensitivity but without obvious
symptoms would undergo life-threatening reactions upon
exposure to NSAIDs, would not be detected. Thus, the
low threshold uncovers those patients with currently mild
NSAID-triggered hypersensitivity for appropriate treatment
before the disease worsens in the future. The latter is vis-
ualised, in part, by Figure 5, sketching schematically the
course of NSAID-triggered hypersensitivity: The symptoms
and underlying disease(s) do not relate in a uniform fashion,
ratherapatternofexacerbationandremissionismorelikean
exponentially growing sinus line. This pattern will be super-
imposed on the residual changes of the underlying disease
and is a further challenge of in vivo and in vitro diagnosis of
AERD.
4.In Vitro Diagnosisof AERD
The change in knowledge and concepts concerning the
pathogenic mechanisms of AERD reﬂects the diversity of in
vitro diagnostic approaches developed during the last cen-
tury.
4.1. Serum-Speciﬁc IgE against NSAIDs (SIgNT). The SIgNT
examines serum or plasma collected from patients suﬀering
from AERD and other manifestations of NSAID-triggered
symptoms. The samples are ﬁlled into tubes coated with
NSAIDs, including derivatives, or with NSAIDs/derivatives
coupled to a carrier. After an incubation and washing step
an anti-IgE or anti-IgG antibody labelled with a tracer (e.g.,
ﬂuorochromeorchromogenﬁnallyconvertedbyanenzyme)
is added. Resulting values of the measurement will identify
diseased patients if the value exceeds a predeﬁned threshold
(cutoﬀ).
Underlying this approach was the observation, that ad-
verse reactions to NASIDs displayed symptoms such as
allergic reactions (the term “allergy” was introduced in1906
by von Pique as immunoglobulin mediated type of reaction
[58]). Therefore, an immunologic reaction was assumed.
Numerousattemptsatdetectinganantibodydirectedagainst
Aspirin, derivatives thereof (e.g., anti-aspiryl antibodies), or
to any other supposed NSAIDs failed to demonstrate an
unequivocal antibody [3]. Even though antibodies were de-
tected in 1940 by Butler et al. [59] and Zhu and colleagues
[60], or propyphenazone-speciﬁc antibodies by the group of
Ferreira [59], or were suspected by the group of Settipane
[61]. These results have not been conﬁrmed in the following
decades[62,63].AlsoserumlevelofIgEinaspirin-intolerant
patients did not diﬀer from non-atopic population [61].
Nevertheless, these investigations contributed some sub-
stantial insights to our current understanding of AERD and
tootherNSAID-triggeredsymptomsasnonimmunologically
mediated diseases. Thus, a SIgNT for the detection of anti-
bodies directed to any NSAID could not be established and is
not available for in vitro diagnosis of AERD.
4.2. Histamine Release Test (HRT). The HRT examines urine
samples from patients exposed to NSAIDs or supernatants
of cell culture medium of peripheral blood cells (PBLs)
incubated in vitro with varying concentrations of diﬀerent
NSAIDs.Journal of Allergy 9
The ﬁrst approach (analysing urinary samples) would
not be classiﬁed as an in vitro test as it aﬀords an in vivo pro-
vocation/exposure of the patient. There are some essential
drawbacks, arguing why this procedure (in vivo challenge)
might not be suitable in some cases (because of, for example,
ethical reasons, age, compliance, technical; see Section 1).
Using PBLs for measurement of histamine release has to be
designated as an in vitro diagnostic test.
The known bronchoconstrictive eﬀect of histamine sti-
mulated the attempt to look for an altered histamine release
in patients with AERD [64]. Early investigations demon-
strated elevated urinary excretion of a histamine metabolite
[65] and elevated plasma histamine levels [66]. These meas-
urements were, however, not conﬁrmed in nasal lavage
upon provocation [67, 68]. Preincubation of leucocytes with
Aspirin failed to alter spontaneous or calcium ionophore-
induced histamine release in patients with AERD [69, 70].
This was conﬁrmed for bronchial lavage [71]a n df o rl e u c o -
cytes by our study performed in vivo as well as in vitro ex-
posure [49, 50]. There are also some inconsistent results in
former studies. Okuda and colleagues reported elevated hist-
amine release induced by platelet-activating factor from
leukocytes of patients with AERD [72], Hosemann and
colleagues measured lower histamine content in polypous
tissue of patients with AERD than in analgesic-tolerant pa-
tients [73], and the group of Stevensson reported elevated
plasma histamine levels in only three of seventeen patients
[74].Theloweﬃciencyofhistaminereleasebyinvitrostimu-
lation according to the CAST-protocol (see CAST) was also
aﬃrmed by a more recent study [75].
EventhoughtheHRTwaspromising,asitdepictsapath-
omechanistic element of AERD, and it might be suitable to
conﬁrm AERD/NSAID sensitivity in speciﬁcally selected pa-
tients (e.g., with an underlying allergic comorbidity), it is
not suggested for routine in vitro diagnosis of patients with
AERD taking into consideration all data currently available.
4.3. Lymphocyte Transformation Test (LTT). The LTT (syn-
onymsarelymphocyteproliferationtestorlymphocytestim-
ulation test) examines the activity of lymphocytes, notably of
T-lymphocytes selected from PBLs upon exposure to vary-
ingNSAIDSatdiﬀerentconcentrations.Mostwidelyusedfor
quantifying the proliferation is the measurement of 3H-thy-
midin uptake by dividing cells from samples of anticoagu-
lated blood.
The relevance of the LTT as model system for analysing
patients with hypersensitivity to Aspirin was discussed more
than40decadesago[76–80].SomeNSAIDsdoinhibitothers
from enhancing the proliferation, but this was not seen
consistently [81–85].
A later study demonstrated an enhanced proliferation of
normal lymphocytes, but a diminished 3H-thymidin uptake
by lymphocytes from patients with AERD [86]. NSAIDs are
consideredsuitableforLTTinvestigation[87].Buttheincon-
sistencyofresults,andthemoreindirectrelation ofdetecting
lymphocyte proliferation to our current pathomechanistic
understanding of AERD, often implicated unclear results.
These ﬁndings questioned the clinical relevance of the LTT
for the detection of adverse reaction to NSAIDs. Therefore,
the LTT is actually not referred to be a suitable tool for in
vitro diagnosis for patients with AERD.
4.4. Platelet Aggregation Testing (PAT). The PAT examines
survival and aggregation of platelets separated from venous
PBLs. The platelets are exposed to varying concentrations of
those NSAIDs which are of interest, for a deﬁned time as
validated by the performing laboratory.
Around 25 years ago it was suggested that platelets
m i g h th a v eap i v o t a lr o l ei nA E R D[ 88–93]. In a subsequent
study, a group led by Picado, detected no diﬀerences in any
indices of platelet function studied between aspirin-tolerant
and patients with AERD despite a slightly elevated aspirin-
triggered PGF2α release [94]. These results are somehow
unexpected, as platelets are known to be potent producer of
eicosanoids.Despitethisapproachandtheimplicationofthe
platelet behaviour in NSAID-triggered symptoms, the PAT
has not been approved for in vitro diagnosis of AERD.
4.5. Serum-PGF2α Test (SPT). The SPT examines serum
selected from peripheral blood. Upon addition of a prede-
ﬁned concentration of ASA in vitro, samples are analysed
using a radio-immunosorbent assay. Samples exceeding a
predeﬁned serum level of PGF2α indicate patients with
AERD.
This approach was introduced in 1991 by Willilams and
colleagues and demonstrated no changes in PGE2 or PGD2
but lower plasma level of PGF2α in patients with AERD
before addition of aspirin, and elevated levels of PGF2α
after addition of aspirin, when compared to aspirin-tolerant
asthmatics [95]. Small concentrations of aspirin given to
platelet suspensions generated PGF2α [96]. This conﬁrmed
the hypothesis of an NSIAD-triggered alteration of prost-
anoid metabolism and altered serum protein binding capac-
ities in patients with AERD. Regrettably, there are no further
publications documenting the routine use of this promising
approach.
4.6. Mediators in Nasal Lavage (MNLT). The MNLT exam-
ines nasal lavage collected from patients exposed in vivo to
lysine aspirin. The nasal lavage is stored appropriately. After
thawing and centrifugation the supernatant is analysed using
speciﬁc enzyme immunoassays for two cytokines, MCP-3
and RANTES [97].
It was proposed that patients with AERD are charac-
terisedmorelikelybyachronicratherthananacuteoverpro-
duction of MCP-3 and RANTES. The MNLT increased our
pathomechanistic understanding of AERD, but an in vivo
provocation step is presupposed. Hence, this approach does
not meet the criteria of an in vitro test. Even though, the
MNLT would be suitable to conﬁrm AERD.
4.7. Exhaled Breath Condensate Eicosanoid Testing (EBCET).
TheEBCETexaminesexhaledbreathcondensateofunexpos-
ed patients with AERD. The condensate is stored until ana-
lysis using an enzyme immunoassays speciﬁc for 8-isopro-
stanes, LTB4,a n dP G E 2. Eicosanoid values exceeding a
predeﬁnedthresholdcharacterisepatientswithapositivetest
outcome.10 Journal of Allergy
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Figure 3: Causal concept of NSAID-triggered eicosanoid imbalance for in vitro diagnosis of AERD. The causal concept of NSAID-trigger
eicosanoid imbalance for in vitro diagnosis of AERD is best allegorised as a tray balancing all parameters (which might be relevant for
the pathway) on a needle. Disease-free individuals: housekeeping PGE2 balances synthesis of pLT (e.g., by induction of endogenous cAMP,
which inhibits synthesis of pLT); expression of enzymes or receptors are unremarkable (A1). Upon exposure to NSAIDs the PGE2 level is
diminished but remains high enough ensuring “uncritical” levels of pLT (even though cAMP might by diminished); expression of enzymes
and/or receptors are not modiﬁed (A2). Patients with AERD: synthesis of housekeeping PGE2 is diminished, but still balances synthesis of
pLT (e.g., by reduced endogenous cAMP); expression of enzymes (up regulation of LTC4-synthase) or receptors (up regulation of cysLT) can
be mutated in some cases (B1). Exposure to NSAIDs/aspirin blocks the COX-pathway causing reduced synthesis of PGE2 (and consequently
further reduced cAMP level), and consequently the metabolism of arachidonic acid is shifted to the 5LO-pathway provoking elevated
synthesis of pLT; expression of enzymes and/or receptors may by altered, but not modiﬁed by NSAIDs (B2).
This study was presented in 2002 by the group of Barnes,
demonstrating elevated 8-isoprostanes and pLT (in ∼50%
of aspirin-intolerant asthmatics), no reduced PGE2 and
unchanged LTB4 in exhaled breath condensate of patients
with AERD exposed to NSAIDs [98] .T h e s eo u t c o m e sa r ei n
line with other studies also highlighting the implication of
leukotrienes and prostanoids regarding diseases of the upper
and lower airways [33, 49, 52, 99–103]. The EBCET was
conﬁrmed by the group of Szczeklik [104]. A very recent
study extended the analysis of eicosanoids in exhaled breath
condensate using gas chromatography/mass spectrometry
and high-performance liquid chromatography/mass spec-
trometry. Before lysine aspirin challenge the amount of 5-
and 15-HETE was higher in aspirin-intolerant asthmatics
than in aspirin-tolerant asthmatics [105].
The approach of the EBCET depicts some of our recent
knowledge on pathomechanisms concerning patients with
AERD. This approach aﬀords special equipment, mostly
located in specialised centres. The EBCET, however, might
become of some diagnostic value and would conﬁrm AERD.
4.8.CellularAllergenStimulationTest(CAST). TheCASTex-
amines cytokine-primed enriched basophilic granulocytes
separated by density-gradient sedimentation from EDTA-
anticoagulated venous PBLs. Cells are incubated for 15 up to
40 minutes with varying concentrations of variable NSAIDs
in combination with complement factor 5a, or anti-IgE as
positive control or vehicle. Reaction is stopped by freezing;
supernatants are analysed by an enzyme immunoassay speci-
ﬁed for cysteinyl-leukotrienes. Values from NSAID-stimu-
lated samples have to exceed a predeﬁned threshold (cutoﬀ)
of cysteinyl-leukotrienes (=pLT) released from a control
sample to reveal a positive test outcome.
The CAST, introduced in 1993 by de Weck detects a bio-
marker with high relevance in AERD [106]. Diﬀerent pro-
tocols were published. A sensitivity of 41 to 82% and a speci-
ﬁcity of 82 to 100% were published. These variances are a
consequence of method, as well as other details (e.g., sample
preparation, selection of NSAID, duration of exposure, in-
clusion/exclusion criteria, age, sex, and number of patients/
controls) [8, 73, 107–110]. Costimulation with complementJournal of Allergy 11
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Figure 4: Framework for diagnostic test outcomes. Schema of “real” world diagnostic test outcomes; test measurement: clinical parameters
like age, sex, ethnic group, height, weight, and so forth or analytical parameters like temperature, IgE, histamine, inter-leukins, lipid
mediators; shaded areas exemplify the false-positive (false-negative) measurement of disease-free (diseased) individuals, respectively; insert:
pictured “ideal” world.
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Figure 5: Hypothetical progress of AERD over time.
factor 5a was claimed by the group of Weber to improve sen-
sitivity [107]; they investigated patients with various under-
lyingdiseases.Loweﬃciencywasreportedwithnodiagnostic
utility and superiority to the HRT [75]. Nevertheless, the
CAST was successfully established for diagnosis of allergies
[109].
According to a more recent study, the CAST uncovers
a pathway which was diﬀerent from the classical IgE-med-
iated pathway. CAST uses doses of ASA for in vitro stimu-
lation causing nonspeciﬁc basophile activation, and thereby
eliminates the usefulness of a cell based diagnostic test for
AERD.Therefore,itwassuggestedthatthe CASTwouldhave
low value in diagnosing AERD and other diseases [108, 110].
4.9. Basophile Activation Test (BAT). The BAT, also named
FAST(Flow-cytometricAllergenStimulationTest),examines
basophilic granulocytes separated from EDTA-anticoagu-
lated venous PBLs. Cells are incubated with varying concen-
trationsofdiﬀerentNSAIDsforupto40minutes.Thereafter,
basophilic granulocytes are double-marked with antibodies
directedtoIgEandCD63(orCD203).Thenumberofpositi-
vely stained basophiles is measured using a ﬂuorescence12 Journal of Allergy
activated ﬂow cytometer combined with appropriate soft-
ware. A positive test outcome is deﬁned by a laboratory-
deﬁned threshold (cutoﬀ) of positively stained basophiles.
The BAT was introduced in 2000 by the group of
de Weck [111]. CD63 is a cell surface glycoprotein that
mediates signal transduction events that play a role in the
regulation of cell development, (platelet) activation, growth
and motility. CD203 represents a transmembrane ecto-nu-
cleotide pyrophosphatase/phospho-diesterase-I enzyme (E-
NPP), which cleaves phosphodiesters and phosphosulfate
bonds. Both proteins are expressed on activated basophils.
Duringthelastdecadefollow-upstudieswereinitiatedtoim-
prove and ensure the technical procedures, thereby using the
term BAT [112–115].
The BAT depicts an altered appearance of granulocytes,
which are known to be implicated in AERD. Variable
values of sensitivity (∼10–64%) and speciﬁcity (∼75–100%)
were published depending on the protocols used (e.g.,
sample preparation, selection of NSAID, duration of expo-
sure,inclusion/exclusioncriteria,age,sex,andnumberofpa-
tients/controls). The clinical use of the BAT is controversially
discussed[112–115],pointingtoinherentfactorsinﬂuencing
the opportunities and limitations of an in vitro diagnostic
test.
4.10. Flow Cytometric Assay and CAST (Flow-CAST). The
Flow-CAST uses two techniques, the CAST (enzyme im-
munoassay)andBAT(ﬂowcytometricassays).Theoutcomes
of both tests are combined.
As reviewed in 2005 by the group of de Weck, the
sensitivity and speciﬁcity varied depending on the NSAID
tested [116]. The global sensitivity was annotated ∼67%, the
speciﬁcity 93%. Combination of BAT with CAST elevated
sensitivity (to ∼73%) but reduced speciﬁcity (to 71%). The
Flow-CAST was proved for diagnosis of beta-lactam allergy
[117]. It was proposed that in case of a negative result, a
NSAID hypersensitivity cannot be excluded and a provoca-
tion challenge remains necessary if clinically indicated.
This approach demonstrates the usefulness of combining
diagnosticproceduresasmentionedintheintroductionpart,
but demonstrates also the drawbacks as explained. From a
practical point of view, performing both tests makes great
demands on laboratory equipment as well as manpower, and
therefore impacts on cost-eﬀectiveness. The advantages of
this procedure compared to others remain to be established.
4.11. Aspirin-Sensitive Patients Identiﬁcation Test (ASPI Test).
The ASPITest examines PBLs exposed in vitro to varying
concentrations of NSAIDs. The release of 15-hydroxyeico-
satetraenoic acid (15-HETE) is analysed using an enzyme
immunoassay speciﬁc for 15-HETE. Values exceeding a pre-
deﬁned amount threshold line (cutoﬀ, ∼6% exceeding basal
release) identify patients with AERD [118].
ThereportbyKowalskiandcolleaguesin2005concluded
that the aspirin-triggered release of 15-HETE from PBLs
does, to some extent, mimic the reactions observed in vivo.
15-HETE was detected in epithelial cells of nasal polypous
tissue as well as in PBLs from patients with AERD, but not in
asthmatics without NSAID hypersensitivity [31, 119, 120].
Already in 1991 the group of Picado demonstrated the
in vivo evidence of elevated release of 15-HETE in nasal
secretions of allergic patients [121]. It was demonstrated,
that a PGE1 analogue (misoprostol) inhibited the aspirin-
triggered 15-HETE release. A recent study investigating eight
ASA-intolerant patients conﬁrmed the elevated level of 15-
HETE [120]. Variable values of sensitivity (∼63–83%) and
speciﬁcity (∼50–82%) were published.
The ASPITest depicts a pathomechanistic link to AERD
and obviously conﬁrms the clinical ﬁnding in patients with
AERD. Hitherto, there are only few promising publications
and future studies will have to prove to which extent the
ASPITest will be applicable for routine use for in vitro
diagnosis of AERD and related diseases.
4.12. Functional Eicosanoid Testing and Typing (FET). The
FET examines PBLs of heparinised venous blood. PBLs are
diluted in an appropriate buﬀer before exposure to ASA,
neuropeptides, andarachidonic acid.Thereactionisstopped
by freezing. Upon thawing and centrifugation the samples
are analysed using speciﬁc enzyme immunoassays for PGE2
and pLT. Measured data are calculated using appropriate
software. The resulting individualised dynamic eicosanoid
pattern is classiﬁed in values ranging from 0.0 to 3.0. This
o u t c o m ei st h e nm o r er o u g h l yc l a s s i ﬁ e da sn o r m a l( 0 . 0t o
0.5), mild (<0.5), moderate (<1.5), and severe (<2 . 5t o3 . 0 ) ;
these values also represent a probability of severity of the
symptoms.
This approach was introduced in 1999 by Sch¨ afer and
colleagues and thereafter improved by integrating the grow-
ing knowledge of pathomechanistic concepts [11, 49–52,
122]. The FET depicts two biomarkers which are intimately
involved in AERD and NSAID-triggered symptoms/diseases.
First studies demonstrated the conﬁrmation of clinically
diagnosed AERD prior to, during provocation, and after
successful treatment [123, 124]. Subsequent studies demon-
strated the diﬀerentiation of non-airway-related but NSAID-
triggered diseases [11, 125–127]. Others applied the FET
for monitoring medical treatment in patients with AERD
[128, 129] or characterisation of pathophysiological aspects
[130]. Values for sensitivity and speciﬁcity varied depending
on the underlying disease (airways: 96 and 89%, skin: 96 and
97%, gastrointestinal tract: 64–98 and 82–89%, resp.) [8].
The FET provides context-dependent cell-based conﬁr-
mative as well as prospective information. This approach
conﬁrms AERD, but also diﬀerentiates and/or characterises
underlying diseases of closely related symptoms; in addition,
depending on the intended diagnostic challenge (as exem-
pliﬁed in Figures 6(a) and 6(b)). The FET diﬀerentiates ob-
viously diﬀerent symptoms of NSAID-triggered hypersensi-
tivity of varying underlying disease. Future studies will have
to demonstrate whether the FET, in addition to conﬁrming
or diﬀerentiating AERD, might provide some prognostic
value in NSAID-triggered diseases.
5. Conclusions
During the last decades our knowledge concerning the path-
ogenic mechanisms, the terminology of NSAID-triggeredJournal of Allergy 13
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Figure 6: (a): FET and NSAID-triggered eicosanoid imbalance of individuals suﬀering from diseases with lower airway symptoms. The FET
was performed and the FET values were calculated according to the total eicosanoid pattern score of [11] using PBLs. Patients suﬀering from
NSAID-triggered bronchoconstrictive symptoms were conﬁrmed and characterised by clinical and in vitro diagnosis. Allergy was ruled out
by medical history, skin test, and in vitro test for total and speciﬁc immunoglobulin. The mean FET value (solid line) of controls, ATA, and
AERD was 0.7, 1.4, and 2.1, respectively. FET values > 1.0 characterise patients with lower airway symptoms. FET values ≥ 1, 8 (dashed
line, potential threshold) diﬀerentiate NSAID-tolerant asthmatics and patients with AERD; ATA: patients suﬀering from aspirin-tolerant
asthma, AERD: patients suﬀering from aspirin exacerbated respiratory disease; (n = 53 for each group, ∗P < 0.05, ∗∗P < 0.01). (b): FET
and functional metabolic diﬀerentiation of patients with and without NSAID-triggered eicosanoid of lower and upper airway symptoms.
The functional metabolic diﬀerentiation (FMD) of subgroups of patient was achieved by in vitro provocation of PBLs and calculation of
the FET value according to the total eicosanoid pattern score of [11], but by amending the FET value by subtracting the diﬀerence of the
sum of the enzymatic capacity (EC) of PG- and LT-synthesis as well as the diﬀerence of the ASA- and neuropeptide-induced eicosanoid
balances (EB) from the primary FET value (EC and EB were calculated according to [11]). The FET-FMD value takes into account two
metabolites of the eicosanoid pathway and their in vitro modiﬁcation by ASA and neuropeptide. The latter had been shown to be intimately
implicated in hyperresponsiveness of airway ([11] and ref. therein). The FET-FMD value reveals the diﬀerentiation of ATA, NP, and AERD,
but without discrimination of ATA and healthy controls. The mean value of FET-FMD (solid line) was 0.4, 0.4, 1.1, and 1.7, for controls,
ATA, NP, and AERD, respectively. The threshold of FET-FMD was ≥1.0 (dashed line) for NSAID-triggered lower and upper symptoms of
the airways. In conclusion, this approach conﬁrmed and characterised NSAID-triggered symptoms by clinical and in vitro diagnosis. ATA:
patients suﬀering from bronchial asthma, but tolerant to NSAIDs, NP: patients suﬀering from nasal polyposis, AERD: patients suﬀering
from aspirin exacerbated respiratory disease with asthmatic symptoms; n = 53 for each group, ns: not signiﬁcant, ∗P < 0.05, ∗∗P < 0.01.
Allergy was ruled out by medical history, skin test and in vitro test of total an speciﬁc immunoglobulin.
symptoms and NSAID-exacerbated diseases (e.g., AERD)
and the technical possibilities have continuously improved.
This facilitated the development of new approaches for
in vitro diagnosis, starting from no in vitro tests available
110 years ago to twelve in vitro tests developed during
the last decades. Some characteristics and suggestions for
intended use of the in vitro tests discussed are summarised in
Table 3.
Our understanding of AERD and NSAID hypersensi-
tivity moved form an immunoglobulin-triggered pathome-
chanism, diagnosed in the serum, to a multiplexed highly
interconnected (eicosanoid) imbalance based on pathogenic
understanding, diagnosing parameters from cell cultures, for
example, genes, enzymes, mediators (lipids, cytokines, pH,
andothers),receptors,andothers.Amultitudeofparameters
were suggested. Surface marker of basophiles and lipid
mediators remained to be the most promising biomarkers.
Dynamic multiparametric approaches were favoured as
compared to static single parametric approaches. A schemat-
ically simpliﬁed pictogram of the COX- and 5-LO pathway
referred to for in vitro diagnosis is given in Figure 2.
The complexity of interacting parameters accounts for
the initial situation where NSAIDs (see Table 2) start to act.
If there is an imbalance of several metabolic and/or genetic
parameters, the block of the COX pathway by NSAIDs will
c a u s ea ne x a c e r b a t i o no fo n eo rm o r eo fp r e s t a g e ( s )o fs y m -
ptoms of a disease. Diagnosing the balance and imbalance of
the eicosanoid cascade might be fundamental for diagnos-
ing and treating NSAID-triggered diseases (see Figures 1
and 3). These approaches might be hampered by high in-
dividual variability of underlying diseases, genetics, enzy-
matic/cellular function/activity, and by inclusion and exclu-
sion criteria during sample collection for in vitro diagnosis.
The (in vitro) test outcome has to be carefully interpreted by
an appropriately trained physician and researcher concern-
ingterminology,inclusion,andexclusioncriteria,testtheory,14 Journal of Allergy
Table 3:Selectedcharacteristicsandsuggestionforuseoftestsdescribedinvitrodiagnosis.ASPITest:aspirin-sensitivepatientsidentiﬁcation
test, BAT: basophile activation test, CAST: cellular antigen stimulation test, EBCET: exhaled breast condensate eicosanoid testing, Flow-
CAST: ﬂowcytometric assay and CAST, HRT: histamine release test, FET functional eicosanoid testing and typing, LTT: lymphocyte
transformation test, MNLT: mediators of nasal lavage test, PAT: platelet aggregation test, SIgNT: serum-speciﬁc immunoglobulin E against
NSAIDstest,SPT:serum-PGF2α test;LT:leukotrienes,PG:prostaglandin,CD:clusterofdiﬀerentiation,HETE:hydroy-eicosatetraenoicacid;
SE: sensitivity, SP: speciﬁcity; PPV: positive predictive value, NPV: negative predictive value; n.v.d.: no values described — not suggested,
(—) suggested, actually not in use, ? suggested upon further validation, (+) suggested with restrictions, + suggested.
In vitro test Test parameter Test sample SE(%) SP (%) PPV (%) NPV (%)
Suggestion
for in vitro
diagnosis
SIgNT IgE, IgG serum n.v.d. n.v.d. n.v.d. n.v.d. —
HRT histamine culture medium,
PBLs n.v.d. n.v.d. n.v.d. n.v.d. —
LTT proliferation lymphocytes n.v.d. n.v.d. n.v.d. n.v.d. —
PAT aggregation platelets n.v.d. n.v.d. n.v.d. n.v.d. (—)
SPT PGF2α serum n.v.d. n.v.d. n.v.d. n.v.d. ?
MNLT MCP-3, RANTES nasal lavage n.v.d. n.v.d. n.v.d. n.v.d. —
EBCET 8-isoprostane exhaled breast
condensate n.v.d. n.v.d. n.v.d. n.v.d. ?
CAST cysLT culture medium,
basophiles 41–82 82–100 ∼96 ∼78 (—)
BAT CD63, CD203 culture medium,
basophiles 60–70 <90 ∼95 ∼56 (—)
Flow-CAST cysLT, CD63 basophiles ∼10–67 ∼75–100 n.v.d. n.v.d. (+)
ASPI Test 15-HETE culture medium,
PBLs 63–83 >50–82 79 86 ?
FET PGE2,p L T culture medium,
PBLs 96 (64–98) 83 (82–89) 90 (70–96) 93 (69–98) +
and last but not least, the most recent hypothesis and models
of pathogenic mechanisms.
All in vitro tests, currently available, consider our current
pathogenic and clinical understanding of AERD. But the
intended use by the clinician or researcher will also account
for the selection of the most appropriate in vitro diagnostic
procedure(e.g., screening purpose, conﬁrmationof a clinical
diagnosis, individual risk assessment, proof of, prognostic
probability, and/or diﬀerentiation of symptomatic appear-
ance, monitoring of treatment, eﬀect of single drugs, and
manymore).Consideringthelimitationsofclinicaldiagnosis
of AERD (see above), the “provocation” test is yet designated
as“goldstandard”inclinicaldiagnosis,butisusuallyrestrict-
ed to conﬁrm acute physical reactions of hyper reactive lower
airways and requires the necessity for patients’ provocation.
But this “gold standard” will fail if AERD is still not thor-
oughly distinctive, a prognostic goal has to be considered, or
provocation is precluded.
The relevance of the diagnostic test outcome and its
interpretation will improve if the users of an in vitro
diagnostic procedure consider all information provided. In
this concern, functional cellular in vitro approaches mimic
some of the complex in vivo processes seen in patients with
AERD. The imbalance of eicosanoids might be a rational
decision-makingmodelforinvitrodiagnosisofAERDaswell
as NSAID-triggered hypersensitivity. Future research will
demonstratewhetherandwhichfunctionalinvitroapproach
will prove to be the “gold standard” of in vitro diagnosis
of AERD to support treatment of patients with AERD and
related diseases.
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